10568707

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Yosef YARDEN et al

Serial No.:

10/568,707

Filed:

December 14, 2006

For:

POLYNUCLEOTIDES, POLYPEPTIDES AND

ANTIBODIES AND USE THEREOF IN TREATING

TSG101-ASSOCIATED DISEASES

Examiner:

Not Yet Assigned

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 Group Art Unit: 1648

Attorney

Docket: 31570

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

> Respectfully submitted, Q. Mogruha

Martin D. Moynihan

Registration No. 40,338

Dated: February 14, 2007

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.P./

FEB 16 2007

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 atent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to resort to a collection information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/568,707 INFORMATION DISCLOSURE December 14, 2006 Filing Date STATEMENT BY APPLICANT Yosef YARDEN et al First Named Inventor 1648 Art Unit (use as many sheets as necessary) Examiner Name Not yet Assigned Attorney Docket Number 31570 10 of Sheet U.S. PATENT DOCUMENTS Name of Patentee or Pages, Columns, Lines, Where Publication Date Cite No. 1 Document Number Examiner Relevant Passages or Relevant Applicant of Cited Document MM-DD-YYYY Initials* Figures Appear Number-Kind Code² (if known)

		FOREIGN	PATENT DOC	UMENTS		-
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
	1	EP 0264166	04-20-1988	Gordon et al.		\vdash
 _	-					
				·		
				I Date		Щ
Examine Signatur	1	/Jeffrey Parkin/		Date Considered	08/17/	2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperw	ork Reduction	Act of 1995, no persons are required to respond to a collection of i	nformation unless it contains a valid	olete if Known					
	Sub	stitute for form 1449A/PTO	Application Number	10/568,707					
		MATION DISCLOSURE	Filing Date December 14, 2006						
\$	STATE	MENT BY APPLICANT	First Named Inventor	Yosef YARDEN ct	al				
	(use	as many sheets as necessary)	Group Art Unit	1648					
		, and the second	Examiner Name	Not yet Assigned					
Sheet	2	Of 10	Attorney Docket Number	31570					
Silect	1-	OTHER PRIOR ART – NON PATEN	IT LITERATURE DOCU	MENTS					
Examiner	Cite	Include name of the author (in CAPITAL LETTERS).	title of the article (when approp	oriate), title of the					
nitials	No.1	item (book, magazine, journal, serial symposium, cata publisher, city and/or cour	alog, etc.) date, page(s), volume- ntry where published.	issue number(s),	T ²				
	2	Aizawa et al. "Kinesin Family in Murine Cer	ntral Nervous System", Th	ne Journal of					
		Cell Biology, 119(5): 1287-1296, 1992.							
	3	Babst et al. "Mammalian Tumor Susceptibili	ty Gene 101 (TSG101) an	id the Yeast					
		Homologue, Vps23p, Both Function in Late	Endosomal Trafficking",	Traffic, 1: 248-					
		258, 2000.							
	4	Clavel et al. "Isolation of A New Human Re	terovirus From West Afric	can Patients					
		With A1DS", Science, 233(4761): 343-346,	1986.						
	5	Cocchi et al. "Identification of RANTES, M	IP-1a < e/b & #62;, and MIP	-1b as the					
	_	Major HIV-Suppressive Factors Produced by	y CD8 ⁺ T C	Cells", Science,					
		270(5243): 1811-1815, 1995.							
	6	Cole et al. "The EBV-Hybridoma Technique and Its Application to Human Lung							
	ľ	Cancer", Monoclonal Antibodies and Cancer Therapy, P.77-96, 1985.							
	7	Coruzzi et al. "Tissue-Specific and Light-Regulated Expression of A Pea Nuclear							
	'	Gene Encoding the Small Subunit of Ribulose-1,5-Bisphosphate Carboxylase", The							
	İ	EMBO Journal, 3: 1671-1680, 1984.							
	8	Cullen "RNA Interference: Antiviral Defens	e and Genetic Tool", Natu	ıre					
		Immunology 3(7): 597-599, 2002.							
	9	Daar et al. "High Concentrations of Recomb	inant Soluble CD4 Are R	equired to					
		Neutralize Primary Human Immunodeficien	cy Virus Type 1 Isolates"	, Proc. Natl.					
		Acad Sci USA, 87: 6574-6578, 1990.							
	10	Davies et al. "Selection of Specific Phage-Display Antibodies Using Libraries							
	1.0	Derived From Chicken Immunoglobulin Genes", Journal of Immunological Methods,							
		186: 125-135, 1995.							
-	11	Demirov et al. "Overexpression of the N-Terminal Domain of TSG101 Inhibits HIV-							
		1 Budding by Blocking Late Domain Functi	on", Proc. Natl. Acad. Sc	i. USA, 99(2):					
		955-960, 2002.							
	12	Deng et al. "Basis for Selection of Improved	d Carbohydrate-Binding S	ingle-Chain					
		Antibodies From Synthetic Gene Libraries"	, Proc. Natl. Acad. Sci. U	SA, 92: 4992-					
		4996 1995							
	13	Deng et al. "Selection of Antibody Single-C	Chain Variable Fragments	With Improved					
	15	Carbohydrate Binding by Phage Display",	The Journal of Biological	Chemistry,					
		269(13): 9533-9538, 1994.							
	14	Edlund et al. "Cell-Specific Expression of t	he Rat Insulin Gene: Evid	ence for Role of					
	***	Two Distinct 5 ^{<font face="Symbol</td"><td>> ¿%o</td>} Flanking E	> ¿%o	lements",					
		Science, 230(4728): 912-916, 1985.							
	15	Englisch et al. "Chemically Modified Oligo	nucleotides as Probes and	Inhbitors",					
	13	Angewandte Chemie, International Edition	in English, 30(6): 613-72	2, 1991 <u> </u>					
		Aligewandte Chemie, international Zerrior	MDED 600 Draw line through cit:	ation if not in conformance	e and not				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF C

Under the Paperw	ork Reduction	Act of 1995, no persons are required to respond to a collection of in	nformation unless it contains a valid	OMB control number.					
	Sut	ostitute for form 1449A/PTO	Application Number	10/568,707					
,	INIEOD'	MATION DISCLOSURE							
			Filing Date	December 14, 2006					
i	STAIL	EMENT BY APPLICANT	First Named Inventor	Yosef YARDEN	et al				
	(use	as many sheets as necessary)	Group Art Unit	1648					
			Examiner Name	Not yet Assigned					
Sheet	3	Of 10	Attorney Docket Number	31570	. <u>.</u>				
		OTHER PRIOR ART – NON PATEN	T LITERATURE DOCU	MENTS					
Examiner	Cite	Include name of the author (in CAPITAL LETTERS),	title of the article (when approp	riate), title of the					
Initials	No.1	item (book, magazine, journal, serial symposium, cata publisher, city and/or coun	try where published.		T ²				
	16		Erickson "Design and Structure of Symmetry-Based Inhibitors of HIV-1 Protease", Perspectives in Drug Discovery and Design, 1: 109-128, 1993.						
	17	Erickson et al. "Design, Activity, and 2.8 A C		Sub>2					
	17	Symmetric Inhibitor Complexed to HIV-1 Pro							
		1990.	otease, science, 247(470	10). 321-333,					
	18	Fingl et al. ""Introduction. General Principles	", The Pharmacological I	Basis of					
		Therapeutics, Sec.I(Chap.1): 1-46, 1975.							
	19	Fishwild et al. "High-Avidity Human IgG? Monoclonal Antibodies From A Novel							
		Strain of Minilocus Transgenic Mice", Nature	e Biotechnology, 14: 845	-851, 1996.					
	20	Freed et al. "Viral Late Domains", Journal of Virology, 76(10): 4679-4687, 2002.							
	21	Gallo et al. "Frequent Detection and isolation of Cytopathic Retroviruses (HTLV-III)							
		From Patients With AIDS and at Risk for AII 1984.	DS", Science, 224(4648):	500-503,					
	22	Garrus et al. "Tsg101 and the Vacuolar Protein Sorting Pathway Are Essential for							
		HIV-1 Budding", Cell, 107: 55-65, 2001.							
	23	Gewirtz "Oligonucleotide Therapeutics: Clothing the Emperor", Current Opinion in							
	 	Molecular Therapeutics, 1(3): 297-306, 1999.							
	24	Giebel et al. "Screening of Cyclic Peptide Phage Libraries Identifies Ligands That							
	- 25	Bind Streptavidin With High Affinities", Biochemistry, 34: 15430-15435, 1995.							
	25	Goila-Gaur et al. "Defects in Human Immunodeficiency Virus Budding and							
		Endosomal Sorting Induced by TSG101 Overexpression", Journal of Virology, 77(11): 6507-6519, 2003.							
	26		oncert With Hsp90 Is Rec	uired for Raf-1					
	20	Grammatikakis et al. "P50cdc37 Acting in Concert With Hsp90 Is Required for Raf-1 Function", Molecular and Cellular Biology, 19(3): 1661-1672, 1999.							
	27	Gurley et al. "Upstream Sequences Required for Efficient Expression of A Soybean							
		Heat Shock Gene", Molecular and Cellular Biology, 6(2): 559-565, 1986.							
	28	Guyader et al. "Genome Organization and Tr							
		Human Immunodeficiency Virus Type 2", N	ature, 326: 662-669, 1987	7. ·					
	29	Hammond et al. "Post-Transcriptional Gene	Silencing by Double-Stra	nded RNA",					
		Nature Reviews: Genetics, 2: 110-119, 2001.	·						
	30	Hermida-Matsumoto et al. "Localization of l	luman Immunodeficiency	y Virus Type 1					
		Gag and Env at the Plasma Membrane by Co	nfocal Imaging", Journal	of Virology,					
		74(18): 8670-8679, 2000.							
	31	Hicke "Protein Regulation by Monobiquitin"	, Nature Reviews: Molec	ular Cell					
		Biology, 2: 195-201, 2001.							
	32	Hoogenboom et al. "By-Passing Immunisation	on. Human Antibodies Fr	om Synthetic					
		Repertoires of Germline VH Gene Segments	Rearranged In Vitro", Jou	urnal of					
		Molecular Biology, 227: 381-388, 1992.	VDED 200 Day 15 - 15 - 15 - 15 - 15 - 15 - 15 - 15						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449A/PTO Application Number 10/568,707 INFORMATION DISCLOSURE Filing Date December 14, 2006 STATEMENT BY APPLICANT Yosef YARDEN et al First Named Inventor Group Art Unit 1648 (use as many sheets as necessary) **Examiner Name** Not yet Assigned Attorney Docket Number 31570 Sheet 4 Of | 10 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), T^2 Initials No.1 publisher, city and/or country where published. Hutv?gner et al. "RNAi: Nature Abhors A Double-Strand", Current Opinion in 33 Genetics & Development, 12: 225-232, 2002 34 Inbar et al. "Localization of Antibody-Combining Sites Within the Variable Portions of Heavy and Light Chains", Proc. Natl. Acad. Sci. USA, 69(9): 2659-2662, 1972. 35 Joazeiro et al. "The Tyrosine Kinase Negative Regulator C-Cbl as A RING-Type, E2-Dependent Ubiquitin-Protein Ligase", Science, 286(5438): 309-312, 1999. 36 Joazeiro et al. "RING Finger Proteins: Mediators of Ubiquitin Ligase Activity", Cell, 102: <u>549</u>-552, 2000. Jones et al. "Replacing the Complementarity-Determining Regions in A Human 37 Antibody With Those From A Mouse", Nature, 321: 522-525, 1986. Jones et al. "Improved Methods for Building Protein Models in Electron Density 38 Maps and the Location of Errors in These Models", Acta Crystallographica, A 47(Part 2): 110-119, 1991. 39 Kahn et al. "The Safety and Pharmacokinetics of Recombinant Soluble CD4 (rCD4) in Subjects With the Aquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex", Annals of Internal Medicine, 112: 254-261, 1990. 40 Katzmann et al. "Ubiquitin-Dependent Sorting Into the Multivesicular Body Pathway Requires the Function oa A Conserved Endosomal Protein Sorting Complex, ESCRT-I", Cell, 106: 145-155, 2001. Katzmann et al. "Receptor Downregulation and Multivesicular-Body Sorting", 41 Nature Reviews: Molecular Cell Biology, 3: 893-905, 2002. 42 Khachigian "DNAzymes: Cutting A Path to A New Class of Therapeutics", Current Opinion in Molecular Therapeutics, 4(2): 119-121, 2002. Kikonyogo et al. "Proteins Related to the Nedd4 Family of Ubiquitin Protein Ligases 43 Interact With the L Domain of Rous Sarcoma Virus and Are Required for Gag Budding From Cells", Proc. Natl. Acad. Sci. USA, 98(20): 11199-11204, 2001 44 Kraulis "MOLSCRIPT: A Program to Produce Both Detailed and Schematic Plots of Protein Structures", Journal of Applied Crystallography, 24: 946-950, 1991. Kronenwett et al. "Oligodeoxyribonucleotide Uptake in Primary Human 45 Hematopoietic Cells Is Enhanced by Cationic Lipids and Depends on the Hematopoietic Cell Subset", Blood, 91(3): 852-862, 1998. Lam et al. "Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV 46 Protease Inhibitors", Science, 263(5145): 380-384, 1994. Lange "Triple Combinations: Present and Future", Journal of Acquired Immune 47 Deficiency Syndromes and Human Retrovirology, 10(Suppl.1): S77-S82, 1995.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Methods in Enzymology, 2(2): 106-110, 1991.

Larrick et al. "PCR Amplification of Antibody Genes", Methods: A Companion to

48

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10568707 - GAU: 1648

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperw	ork Reduction	Act of 1995, no persons are required to respond to a collection of i	information unless it contains a valid	OMB control number.					
	Sut	ostitute for form 1449A/PTO	Application Number	10/568,707					
]	INFOR	MATION DISCLOSURE	Filing Date	December 14, 2006					
	STATE	MENT BY APPLICANT	First Named Inventor	Yosef YARDEN e	t al				
	(use	as many sheets as necessary)	Group Art Unit	1648					
	(mac	as many sheets as necessary,	Examiner Name	Not yet Assigned					
	T-5	TOS 110	Attorney Docket Number	31570					
Sheet	5	Of 10 OTHER PRIOR ART – NON PATEN	_ '		-				
Examiner	Cite	Include name of the author (in CAPITAL LETTERS),							
nitials	No.1	item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	49	Lavigne et al. "Enhanced Antisense Inhibitor	of Human Immunodefici	ency Virus					
		Type 1 in Cell Cultures by DLS Delivery Sys	stem", Biochemical and B	iophysical					
	_	Research Communications, 237: 566-571, 19	997.						
	50	Li et al. "Tsg101: A Novel Tumor Susceptib	ility Gene Isolated by Con	trolled					
		Homozygous Functional Knockout of Allelia	Loci in Mammalian Cell	s", Cell, 85:					
		319-329, 1996.	Constal and discoun						
	51	Li et al. "The TSG101 Tumor Susceptibility							
		Band P15 and 1s Mutated in Human Breast C	ancer", Cell, 88: 143-154	, 1997.					
	52	Lonberg et al. "Human Antibodies From Transgenic Mice", International Reviews of							
		Immunology, 13: 65-93, 1995.							
	53	Lonberg et al. "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications", Nature, 368: 856-859, 1994.							
		Luft "Clinical Implications. Making Sense Out of Antisense Oligodeoxynucleotide							
	54	Delivery: Getting There is Half the Fun", Journal of Molecular Medicine, 76: 75-76,							
		Delivery: Getting There is Half the Fun", Journal of Molecular Medicine, 76: 73-76, 1998.							
	55	Marks et al. "By-Passing Immunization: Building High Affinity Human Antibodies							
	33	by Chain Shuffling", Bio/Technology, 10: 779-783, 1992.							
	56	Marks et al. "By-Passing Immunization. Human Antibodies From V-Gene Libraries							
	30	Displayed on Phage", Journal of Molecular Biology, 222: 581-597, 1991.							
-	57	Martin-Serrano et al. "A Bipartite Late-Budding Domain in Human							
	"	Immunodeficiency Virus Type 1", Journal of Virology, 77(22): 12373-12377, 2003.							
	58	Martin-Serrano et al. "Role of ESCRT-1 in Retroviral Budding", Journal of Virology,							
		77(8): 4794-4804, 2003.							
	59	Martin-Serrano et al. "HIV-1 and Ebola Virus Encode Small Peptide Motifs That							
		Recruit Tsg101 to Sites of Particle Assembly	y to Facilitate Egress", Na	ture Medicine,					
		7(12): 1313-1319, 2001.							
	60	Matveeva et al. "Prediction of Antisense Oli	gonucleotide Efficacy by	In Vitro					
		Methods", Nature Biotechnology, 16: 1374-	1375, 1998.						
· · · · ·	61	Mauro et al. "STI571: A Paradigm of new A		utics", Journal					
		of Clinical Oncology, 20(1): 325-334, 2002.							
	62	Mitsuya et al. "Molecular Targets for AIDS	Therapy", Science, 249(4)	976): 1533-					
		1544, 1990.							
	63	Mitsuya et al. "Targeted Therapy of Human		Kelated					
		Disease", The FASEB Journal, 5: 2369-238							
	64	Morrison "Success in Specification", Nature	, 368: 812-813, 1994.	T					
	65	Myers et al. "Tsg101, An Inactive Homolog	ue of Ubiquitin Ligase E2	, interacts					
		Specifically With Human Immunodeficience	y Virus Type 2 Gag Polyp	rotein and					
		Results in Increased Levels of Ubiquitinated	Gag", Journal of Virolog	y, /6(22):					
AND THE YEAR		11226-11235, 2002.	toro non Day Van de la la						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office,

10568707 - GAU: 1648

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

	Sul	bstitute for form 1449A/PTO		olete if Known					
,	MEAD	MATION DISCLOSUDE	Application Number	10/568,707					
		MATION DISCLOSURE	Filing Date December 14, 20		6				
	STATE	EMENT BY APPLICANT	First Named Inventor	Yosef YARDEN	et al				
	(use	as many sheets as necessary)	Group Art Unit	1648					
			Examiner Name	Not yet Assigned	-				
Sheet	6	Of 10	Attorney Docket Number	31570	-				
		OTHER PRIOR ART – NON PATEN	T LITERATURE DOCU	MENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS) item (book, magazine, journal, serial symposium, cat publisher, city and/or cou	alog, etc.) date, page(s), volume-	riate), title of the issue number(s),	T ²				
	66	Naldini et al. "Efficient Transfer, Integration		n Expression	•				
		of the Transgene in Adult Rat Brains Injecte							
		Acad. Sci. USA, 93: 11382-11388, 1996.		, - 1001 11001					
-	67	Neuberger "Generating High-Avidity Human	n Mabs in Mice" Nature B	liotechnology					
	"	14: 826, 1996.	ii whee , i daidle D	noteciniology,					
	68		· What's at the INTERSEC	TION?"					
	100	O'Bryan et al. "Mitogenesis and Endocytosis: What's at the INTERSECTION?",							
	69	Oncogene, 20: 6300-6308, 2001. Ott et al. "Retroviruses Have Differing Requirements for Proteasome Function in the							
	09								
	70	Budding Process", Journal of Virology, 77(6): 3384-3393, 2003. Pack et al. "Improved Bivalent Miniantibodies, With Identical Avidity as Whole							
	70	Antibodies, Produced by High Cell Density Fermentation of Escherichia Coli",							
			ıa Colı",						
		Bio/Technology, 11: 1271-1277, 1993.							
	71	Perelson et al. "HIV-1 Dynamics In Vivo: Virion Clearance Rate, Infected Cell Life-							
	ļ	Span, and Viral Generation Time", Science, 271(5255): 1582-1586, 1996.							
	72	Pinkert et al. "An Albumin Enhancer Located 10 Kb Upstream Functions Along With							
		Its Promoter to Direct Efficient, Liver-Specific Expression in Transgenic Mice",							
		Gencs & Devclopment, 1: 268-276, 1987.							
	73	Pornillos et al. "Mechanisms of Enveloped RNA Virus Budding", Trends in Cell							
		Biology, 12(12): 569-579, 2002.							
	74	Pornillos et al. "Structure of the Tsg101 UEV Domain in Complex With the PTAP							
		Motif of the H1V-1 P6 Protein", Nature Structural Biology, 9(11): 812-817, 2002.							
	75	Pornillos et al. "Structure and Functional Inte							
		The EMBO Journal, 21(10): 2397-2406, 200		, l					
	76	Porter "The Hydrolysis of Rabbit ?-Globulin		stalline					
		Papain", Biochemical Journal, 73: 119-126,		-					
	77	Presta "Antibody Engineering", Current Opi		2: 593-596					
		1992.		, ,					
	78	Puffer et al. "Equine Infectious Anemia Viru	s Utilizes as VXXI. Motif	Within the					
	'	Late Assembly Domain of the Gag P9 Protein							
		6546, 1997.	ii , voumai or virology, /	1(7). 0371-					
	79	Rajur et al. "Covalent Protein-Oligonucleotic	de Conjugates for Efficient	Delivery of					
	13			Delivery of					
-	90	Antisense Molecules", Bioconjugate Chemis		222, 222, 220					
	80	Riechmann et al. "Reshaping Human Antibo	ales for Therapy", Nature,	<i>332</i> : <i>323</i> - 329,					
_	 	1988.							
	81	Davidkova et al. "Mechanism of Action of A		otides",					
		Antisense Research and Applications, CRC	Press, P.276-278, 1993.						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. The Third Through Codes of Uspto Patent Documents at www.uspto.gov or MPEP 901.04. Through Codes of Uspto Patent Documents, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperw	ork Reduction	Act of 1995, no persons are required to respond to a collection of in							
	Sul	ostitute for form 1449A/PTO		olete if Known					
,	INEOD	MATION DISCLOSURE	Application Number 10/568,707 Filing Date December 14, 2006						
			Filing Date						
	STATE	MENT BY APPLICANT	First Named Inventor	Yosef YARDEN e	et al				
	(use	as many sheets as necessary)	Group Art Unit	1648					
			Examiner Name	Not yet Assigned					
Sheet	7	Of 10	Attorney Docket Number	31570					
		OTHER PRIOR ART – NON PATEN	T LITERATURE DOCU	MENTS					
Examiner	Cite	Include name of the author (in CAPITAL LETTERS),	tille of the article (when approp	riate), title of the					
Initials	No. ¹	item (book, magazine, journal, serial symposium, catal publisher, city and/or coun	try where published.		T ²				
	82	Davidkova et al. "Pharmacological Inhibition		ense Research					
		and Applications, CRC Press, P.289-302, 199							
	83	Santoro et al. "A General Purpose RNA-Clea	ving DNA Enzyme", Prod	c. Natl. Acad.					
		Sci. USA, 94: 4262-4266, 1997.							
	84	Schooley et al. "Recombinant Soluble CD4 T							
		Immunodeficiency Syndrome (AIDS) and AI	DS-Related Complex", A	nnals of .					
		Internal Medicine, 112: 247-253, 1990.							
	85	Schubert et al. "Augementation of Virus Secr							
		Virus Type I Vpu Protein Is Cell Type Indep	endent and Occurs in Cul	tured Human					
		Primary Macrophages and Lymphocytes", Journal of Virology, 69(12): 7699-7711, 1995.							
	86	Schubert et al. "Proteasome Inhibition Interferes With Gag Polyprotein Processing,							
		Release, and Maturation of HIV-1 and HIV-2", Proc. Natl. Acad. Sci. USA, 97(24):							
		13057-13062, 2000.							
	87	Sharp "RNA Interference - 2001", Genes & I	Development, 15: 485-490), 2001.					
	88	Smith et al. "Blocking of HIV-1 Infectivity by	y A Soluble, Secreted For	rm of the CD4					
		Antigen", Science, 238(4834): 1704-1707, 1987.							
	89	Studier et al. "Use of T7 RNA Polymerase to Direct Expression of Cloned Genes",							
		Methods in Enzymology, 185(Chap.6): 60-89, 1990.							
	90	Takamatsu et al. "Expression of Bacterial Chloaramphenicol Acetyltransferase Gene							
		in Tobacco Plants Mediated by TMV-RNA", The EMBO Journal, 6(2): 307-311,							
		1987.			_				
	91	Teich et al. "Pathogenesis of Lentiviruses", RNA Tumor Viruses, CSH-Press,							
		Chap.14: 949-956, 1984.							
	92	Tonkinson et al. "Antisense Oligodeoxynucle	eotides as Clinical Therap	eutics Agents",					
		Cancer Investigation, 14(1): 54-65, 1996.							
	93	Tuschl "RNA Interference and Small Interfer	ing RNAs", CHEMBIOC	CHEM, 2: 239-					
		245, 2001.							
	94	Tzahar et al. "A Hierarchical Network of Inte	erreceptor Interactions De	termines					
		Signal Transduction by Neu Differentiation I	actor/Neuregulin and Ep	idermal					
		Growth Factor", Molecular and Cellular Biol	ogy, 16(10): 5276-528 <u>7,</u>	1996.					
	95	Uno et al. "Antisense-Mediated Suppression							
		Inhibits Pleural Dissemination of Human Car	ncer Cells", Cancer Resea	rch, 61: 7855-					
		7860, 2001.							
	96	Varmus "Retroviruses", Science, 240(4858):	1427-1435, 1988.						
	97	Verhoeyen et al. "Reshaping Human Antiboo		ozyme					
		Activity", Science, 239(4847): 1534-1536, 1	988						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\) Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \(^9\) Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

nark Office: U.S. DEPARTMENT OF COMMERCE

75-1 D	1.0.1	A . C1005	U.S. Patent and Trademark O	one: U.S. DEPARTM	ENT OF COM				
Under the Paperw	ork Reduction	Act of 1995, no persons are required to respond to a collection of i		olete if Known					
	Sut	ostitute for form 1449A/PTO	Application Number	10/568,707					
]	INFOR	MATION DISCLOSURE	Filing Date	December 14, 200	6				
i	STATE	MENT BY APPLICANT	First Named Inventor	Yosef YARDEN e	t al				
	(use	as many sheets as necessary)	Group Art Unit	1648					
		•	Examiner Name	Not yet Assigned					
Sheet	8	Of 10	Attorney Docket Number	31570					
neet	-	OTHER PRIOR ART – NON PATEN							
C	Cite	Include name of the author (in CAPITAL LETTERS),							
Examiner Initials	No.1	item (book, magazine, journal, serial symposium, cate publisher, city and/or cour	llog, etc.) date, page(s), volume-		T ²				
	98	VerPlank et al. "Tsg101, A Homologue of U	biquitin-Conjugating (E2)	Enzymes,					
		Binds the L Domain in HIV Type I Pr55 Ga	g", Proc. Natl. Acad. Sci.	USA, 98(14):					
		7724-7729, 2001.							
	99	Walton et al. "Prediction of Antisense Oligor	nucleotide Binding Affinit	y to A					
		Structured RNA Target", Biotechnology and	Bioengineering, 65(1): 1-	9, 1999.					
	100	Wang et al. "Low Frequency of TSG101/CC	Wang et al. "Low Frequency of TSG101/CC2 Gene Alterations in Invasive Human						
		Breast Cancers", Oncogene, 16: 677-679, 19	98 <i>.</i>						
	101	Waterman et al. "Molecular Mechanisms Underlying Endocytosis and Sorting of							
		ErbB Receptor Tyrosine Kinases", FEBS Let	ters, 490: 142-152, 2001.						
	102	Waterman et al. "The RING Finger of C-Cbl Mediates Desensitization of the Epidermal Growth Factor Receptor", The Journal of Biological Chemistry, 274(32): 22151-22154, 1999.							
	103	Rogers et al. "Gene Transfer in Plants: Production of Transformed Plants Using Ti							
		Plasmid Vectors", Methods for Plant Molecular Biology, Academic Press,							
	İ	Sec.VIII(Chap.26-28): 423-463, 1988.							
	104	Weitzel et al. "Molecular Genetic Changes Associated With Ovarian Cancer",							
		Gynecologic Oncology, 55: 245-252, 1994.							
	105	Welch etc. "Ribozyme Gene Therapy for Hepatitis C Virus Infection", Clinical and							
		Diagnostic Virology, 10: 163-171, 1998.							
	106	Welch et al. "Expression of Ribozymes in Gene Transfer Systems to Modulate Target							
		RNA Levels", Current Opinion in Biotechno	logy, 9: 486-496, 1998.						
	107	Whitlow et al. "Single-Chain Fv Proteins and Their Fusion Proteins", Methods: A							
		Companion to Methods in Enzymology, 2(2)	Companion to Methods in Enzymology, 2(2): 97-105, 1991.						
	108	Wills et al. "Form, Function, and Use of Retroviral Gag Proteins", AIDS, 5: 639-654,							
		1991.							
	109	Wilson et al. "A Genetic Method for Defining DNA-Binding Domains: Application							
	4	to the Nuclear Receptor NGF1-B", Proc. Nat	I. Acad. Sci. USA, 90: 91	86-9190, 1993.					
	110	Winoto et al. "A Novel, Inducible and T Cel	I-Specific Enhancer Locat	ted at the 3' End					
		of the T Cell Receptor Alpha Locus", The E	MBO Journal, 8(3): 729-7	/33, 1989.					
	111	Wlodawer et al. "Structure-Based Inhibitors	of HIV-1 Protease", Annu	ual Reviews of					
		Biochemistry, 62: 543-585, 1993.							
	112	Yarchoan et al. Phase 1 Study of the Admini	stration of Recombinant S	Soluble CD4					
		(rCD4) by Continuous Infusion to Patients V							
		5th International Conference on AIDS, Post	er Session, Basic Research	n, M.C.P.137,					
		P.564, 1989. Abstract.							
	113	Young "The Three-Dimensional Structures	of A Polysaccharide Bind	ing Antibody to					
		Cryptococcus Neoformans and Its Complex	With A Phage Display Li	brary:					
		Implications for the Identification of Peptide	e Mimotopes", Journal of	Molecular					
		Diology 274, 622 624 1007							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Biology, 274: 622-634, 1997.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office,

10568707 - GAU: 1648

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperw	ork Reduction	Act of 1995, no persons are required to respond to a collection of in	formation unless it contains a valid	OMB control number.					
	Sub	ostitute for form 1449A/PTO		lete if Known					
_			Application Number	10/568,707					
		MATION DISCLOSURE	Filing Date	December 14, 2006					
	STATE	MENT BY APPLICANT	First Named Inventor	Yosef YARDEN	et al				
	(use	as many sheets as necessary)	Group Art Unit	1648					
			Examiner Name	Not yet Assigned					
Sheet	9	Of 10	Attorney Docket Number	31570	-				
		OTHER PRIOR ART – NON PATEN	LITERATURE DOCU	MENTS					
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), 1	title of the article (when approp	riate), title of the					
Initials	No.1	item (book, magazine, journal, serial symposium, catal	og, etc.) date, page(s), volume-	issue number(s),	T^2				
		publisher, city and/or count	publisher, city and/or country where published. Lai et al. "Differentiation of Hdm2-Mediated P53 Ubiquitination and Hdm2						
	114								
		Autoubiquitination Activity by Small Molecu	iar weight inhibitors", Pi	oc. Nati.					
	_ļ	Acad. Sci. USA, 99(23): 14734-14739, 2002.							
	115	Aoki et al. "In Vivo Transfer Efficiency of Ar	itisense Oligonucleotides	Into the					
		Myocardium Using HVJ-Liposome Method",	Biochemical and Biophy	sical Research					
		Communications, 231: 540-545, 1997.							
	116	Jones et al. "Current Trends in Molecular Recognition and Bioseparation", Journal of							
		Chromatography A, 707: 3-22, 1995.							
	117	Banerji et al. "A Lymphocyte-Specific Cellular Enhancer Is Located Downstream of							
		the Joining Region in Immunoglobulin Heavy Chain Genes", Cell, 33: 729-740,							
		1983.							
_	118	Barre-Sinoussi et al. "Isolation of A T-Lymphotrophic Retrovirus From A Patient at							
	'''	Risk for Acquired Immune Deficiency Syndrome (AIDS)", Science, 220(4599): 868-							
		871, 1983,							
 	119	Bernstein et al. "Role for A Bidentate Ribonuclease in the Initiation Step of RNA							
	119	Interference", Nature, 409: 363-366, 2001.							
	120	Bird et al. "Single-Chain Antigen-Binding Proteins", Science, 242(4877): 423-426,							
	120								
	121	1988. Dish on at all UTSC 101/Mammalian VDS22 and Mammalian VDS28 Interact Directly							
	121	Bishop et al. "TSG101/Mammalian VPS23 and Mammalian VPS28 Interact Directly							
		and Are Recruited to VPS4-Induced Endosomes", The Journal of Biological							
		Chemistry, 276(15): 11735-11742, 2001.							
	122	Bitter et al. "Expression and Secretion Vectors for Yeast", Methods in Enzymology,							
		153(Chap.33): 516-544, 1987.							
	123	Blazevic et al. "Helper and Cytotoxic T Cell							
	i	Individuals to Synthetic Peptides of HIV Typ	e I Rev", AIDS Research	and Human					
		Retroviruses, 11(11): 1335-1342, 1995.							
	124	Boerner et al. "Production of Antigen-Specifi	c Human Monoclonal Ar	itibodies From					
	į	In Vitro-Primed Human Splenocytes", The Jo	ournal of Immunology, 14	17(1): 86-95,					
		1991.							
	125	Brantl "Antsense-RNA Regulation and RNA	Interference", Biochimic	a et Biophysica					
		Acta, 1575: 15-25, 2002.							
	126	Breaker et al. "A DNA Enzyme With Mg2+Dependent RNA Phosphoesterase							
	-2	Activity", Chemistry & Biology, 2: 655-660, 1995.							
	127	Brisson et al "Expression of A Bacterial Gen	e in Plants by Using A V	iral Vector".					
	1 1 2 /	Brisson et al. "Expression of A Bacterial Gene in Plants by Using A Viral Vector", Nature, 310: 511-514, 1984.							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

10568707 - GAU: 1648

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE ction of information unless it contains a valid OMB control number.

Application Number 10/568,707 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) et 10 Of 10 Attorney Docket Number 31570 OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS miner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book magazine inumal serial symposium, catalog, etc.) date, page(s), volume-issue number(s), T ²	Under the Paperwo	ork Reduction	Act of 1995, no persons are required to respond to a collection of in	formation unless it contains a valid Comp	olete if Known				
STATEMENT BY APPLICANT (use as many sheets as necessary) Examiner Name Of 10 OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. 128 Broglie et al. "Light-Regulated Expression of A Pea Ribulose-1,5-Bisphosphate Carboxylase Small Subunit Gene in Transformed Plant Cells", Science, 224(4651): 838-843, 1984. 129 Byrne et al. "Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477, 1989. 130 Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988. 131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,		Sub	stitute for form 1449A/PTO						
et 10 Of 10 Attorney Docket Number 31570 OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS miner ials No. 1 Include name of the author (in CAPITAL LETTERS), till of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. 128 Broglie et al. "Light-Regulated Expression of A Pea Ribulose-1,5-Bisphosphate Carboxylase Small Subunit Gene in Transformed Plant Cells", Science, 224(4651): 838-843, 1984. 129 Byrne et al. "Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477, 1989. 130 Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988. 131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,	I	NFOR	MATION DISCLOSURE	Filing Date	December 14, 20	06			
et 10 Of 10 Attorney Docket Number 31570 OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. 128 Broglie et al. "Light-Regulated Expression of A Pea Ribulose-1,5-Bisphosphate Carboxylase Small Subunit Gene in Transformed Plant Cells", Science, 224(4651): 838-843, 1984. 129 Byrne et al. "Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477, 1989. 130 Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988. 131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,	\$	STATE	MENT BY APPLICANT	First Named Inventor	Yosef YARDEN	et al			
et 10 Of 10 Attorney Docket Number 31570 OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. 128 Broglie et al. "Light-Regulated Expression of A Pea Ribulose-1,5-Bisphosphate Carboxylase Small Subunit Gene in Transformed Plant Cells", Science, 224(4651): 838-843, 1984. 129 Byrne et al. "Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477, 1989. 130 Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988. 131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,		(use	as many sheets as necessary)	Group Art Unit	1648				
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. 128 Broglie et al. "Light-Regulated Expression of A Pea Ribulose-1,5-Bisphosphate Carboxylase Small Subunit Gene in Transformed Plant Cells", Science, 224(4651): 838-843, 1984. 129 Byrne et al. "Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477, 1989. 130 Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988. 131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,		(****		Examiner Name	Not yet Assigned	1			
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. 128 Broglie et al. "Light-Regulated Expression of A Pea Ribulose-1,5-Bisphosphate Carboxylase Small Subunit Gene in Transformed Plant Cells", Science, 224(4651): 838-843, 1984. 129 Byrne et al. "Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477, 1989. 130 Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988. 131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,	Sheet	Oct 10 Attorney Docket Number 31570							
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. 128 Broglie et al. "Light-Regulated Expression of A Pea Ribulose-1,5-Bisphosphate Carboxylase Small Subunit Gene in Transformed Plant Cells", Science, 224(4651): 838-843, 1984. 129 Byrne et al. "Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477, 1989. 130 Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988. 131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,	Silect	+	OTHER PRIOR ART – NON PATEN	T LITERATURE DOCU	MENTS				
item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. 128 Broglie et al. "Light-Regulated Expression of A Pea Ribulose-1,5-Bisphosphate Carboxylase Small Subunit Gene in Transformed Plant Cells", Science, 224(4651): 838-843, 1984. 129 Byrne et al. "Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477, 1989. 130 Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988. 131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,	F	Cita	Include name of the author (in CAPITAL LETTERS)	title of the article (when approp	riate), title of the				
Broglie et al. "Light-Regulated Expression of A Pea Ribulose-1,5-Bisphosphate Carboxylase Small Subunit Gene in Transformed Plant Cells", Science, 224(4651): 838-843, 1984. 129 Byrne et al. "Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477, 1989. 130 Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988. 131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,	Examiner Initials	No.1	item (book magazine journal, serial symposium, cata	llog, etc.) date, page(s), volume-	issue number(s),	T^2			
Carboxylase Small Subunit Gene in Transformed Plant Cells", Science, 224(4651): 838-843, 1984. 129 Byrne et al. "Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477, 1989. 130 Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988. 131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,		128	Broglie et al "Light-Regulated Expression of	A Pea Ribulose-1,5-Bisp	hosphate				
Byrne et al. "Multiplex Gene Regulation: A Two-Tiered Approach to Transgene Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477, 1989. 130 Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988. 131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,		128	Carboxylase Small Subunit Gene in Transfor	med Plant Cells", Science	e, 224(4651):				
Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477, 1989. 130 Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988. 131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,		129	Byrne et al "Multiplex Gene Regulation: A]	Two-Tiered Approach to	Transgene				
Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988. 131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,		12)	Regulation in Transgenic Mice", Proc. Natl. Acad. Sci. USA, 86(14): 5473-5477,						
Cell Receptor Loci", Advances in Immunology, 43: 235-275, 1988. 131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,		130	Calame et al. "Transcriptional Controlling Elements in the Immunoglobulin and T						
131 Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,		130	Cell Recentor Loci" Advances in Immunology, 43: 235-275, 1988.						
Breast and Ovarian Cancers", Journal of the Society for Gynecologic Investigation, 5: 281-285, 1998. 132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,		131	Carney et al. "Aberrant Splicing of the TSG101 Tumor Suppressor Gene in Human						
132 Carson "Ribbons", Methods in Enzymology, 277: 493-505, 1997. 133 Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,			Breast and Ovarian Cancers", Journal of the Society for Gynecologic investigation, 5: 281-285, 1998.						
Chang et al. "Analysis of TSG101 Tumour Susceptibility Gene Transcripts in Cervical and Endometrial Cancers", British Journal of Cancer, 79(3/4): 445-450,		132	Carson "Ribbons", Methods in Enzymology,	277: 493-505, 1997.					
	<u> </u>	133	Changet at "Analysis of TSG101 Tumour S	Susceptibility Gene Transo	cripts in				
			Cervical and Endometrial Cancers", British J	Journal of Cancer, 79(3/4)): 445-450, 				
						<u> </u>			
		_							
		_							
						<u> </u>			
						J			

		<u> </u>	
Signature	/ Jeffrey Parkin/	Considered	08/17/2009
Signature		· ·	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection of information is required by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10568707 - GAU: 1648

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

ork Reduction A	Act of 1995, no persons ar	e required t	o respond to a collection	of information unless it contains	Complete if Known		
Substitute for form 1449A/PTO							
INFORMATION DISCLOSURE						2006	
HAIL	VIENT DI A		AINI	First Named Invent		in et ai	
(use as many sheets as necessary)							
				Examiner Name	Not yet Assign	ed	
To		Of	10	Attorney Docket Nu	mber 31570		
 	OTHER P				1		
Cite	Include name of the	e author (i	n CAPITAL LETTER	S), title of the article (when	appropriate), title of the		
No.1	iicm (book, magaz	ine, journ	al, serial symposium, oublisher, city and/or o	catalog, etc.) date, page(s), vecountry where published.	olume-issue number(s),	T ²	
98	VerPlank et al. "	Tsg101,	A Homologue of	Ubiquitin-Conjugating	g (E2) Enzymes,		
			HV Type 1 Pr55	Gag", Proc. Natl. Acad.	Sci. USA, 98(14):		
	7,724-7729, 2001	•			CC* 1		
99	Walton et al. "Pr	ediction	of Antisense Oli	gonucleotide Binding A	Affinity to A		
	Structured RNA	Target"	, Biotechnology a	na Bioengineering, 65(1J. 1-9, 1999.		
100	Wang et al. "Low	V Freque	ency of TSG101/0	1998	n invasive numan		
Breast Cancers", Oncogene, 16: 677-679, 1998.							
Waterman et al. "Molecular Mechanisms Underlying Endocytosis and Solding of ErbB Pacentor Tyrosine Kinases" FFBS Letters, 490: 142-152, 2001.							
102 Waterman et al. "The RING Finger of C-Cbl Mediates Desensitization of the							
Epidermal Growth Factor Receptor", The Journal of Biological Chemistry, 274(32):							
	22151-22154, 19	999.					
103	Rogers et al. "Ge	ene Trar	nsfer in Plants: Pro	oduction of Transforme	d Plants Using Ti		
Plasmid Vectors", Methods for Plant Molecular Biology, Academic Press,							
Sec.VIII(Chap.26-28): 423-463, 1988.							
104 Weitzel et al. "Molecular Genetic Changes Associated With Ovarian Cancer",							
Gynecologic Oncology, 55: 245-252, 1994.							
Welch etc. "Ribozyme Gene Therapy for Hepatitis C Virus Infection", Clinical and							
Diagnostic Virology, 10: 163-171, 1998.							
Welch et al. "Expression of Ribozymes in Gene Transfer Systems to Modulate Target							
RNA Levels", Current Opinion in Biotechnology, 9: 480-490, 1996.							
107 Whitlow et al. "Single-Chain by Proteins and Their Fusion Proteins, Methods in Enzymology 2(2): 97-105 1991							
Companion to Methods III Enzylliology, 2(2), 97-103, 1991.							
108 /		m, runc	ction, and Osc of i	Actionnal Oag Froteins	, 11122, 21 00 2 00 1,		
1991. 100 Wilson et al. "A Genetic Method for Defining DNA-Binding Domains: Application							
to the Nuclear Recentor NGFI-B". Proc. Natl. Acad. Sci. USA, 90: 91							
110	Winoto et al. "A	Novel.	Inducible and T	Cell-Specific Enhancer	Located at the 3' End	i	
'''	<i>7</i> 29-733, 1989						
111	Wlodawer et al.	"Struct	ure-Based Inhibit	ors of HIV-1 Protease"	, Annual Reviews of		
	Biochemistry, 6	2: 543-	585, 1993.				
112	Yarchoan et al.	Phase I	Study of the Adm	ninistration of Recombi	nant Soluble CD4		
	(rCD4) by Cont	inuous l	Infusion to Patien	ts With A1DS or ARC"	, Proceedings of the		
			rence on AIDS, P	oster Session, Basic Re	search, M.C.P.137,		
	P.564, 1989. Al	ostract.			73.1 31 A 4.11 7 4		
113	Young "The Th	ree-Din	iensional Structur	es of A Polysaccharide	Binding Antibody to)	
	Cryptococcus N	leoform	ans and Its Comp	lex With A Phage Disp	iay Library:		
	Implications for	r the Ide	ntification of Pep	tide Mimotopes", Journ	iai of iviolecular		
	Subs NFORN STATE (use a a a a a a a a a a	NFORMATION DISTATEMENT BY A (use as many sheets as a large of the item (book, magaz) 98 VerPlank et al. "Binds the L Dom 7724-7729, 2001 99 Walton et al. "Pr Structured RNA 100 Wang et al. "Low Breast Cancers", 101 Waterman et al. ErbB Receptor Town 22151-22154, 19 102 Waterman et al. Epidermal Grow 22151-22154, 19 103 Rogers et al. "Governo Plasmid Vectors Sec. VIII(Chap. 2) 104 Weitzel et al. "Nown Gynecologic On 105 Welch etc. "Ribon Diagnostic Viro Welch et al. "Ex RNA Levels", Companion to Now 108 Wills et al. "For 1991. 109 Wilson et al. "A to the Nuclear Resident of the T Cell Resident of the T Ce	NFORMATION DISCLO STATEMENT BY APPLIC (use as many sheets as necessar 8	NFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 8	NFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) String Date	Substitute for form 1449APTO NFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 8 Of 10	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language

I ransiation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office,